Published in N Engl J Med on November 16, 2006
Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) | NCT00211120
Predialysis nephrology care of older patients approaching end-stage renal disease. Arch Intern Med (2011) 5.11
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int (2008) 3.34
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant (2014) 2.91
The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. Am J Med (2013) 2.77
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol (2008) 2.72
Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol (2008) 2.63
Does AKI truly lead to CKD? J Am Soc Nephrol (2012) 2.61
Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood (2007) 2.51
Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest (2008) 2.45
The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int (2012) 2.35
Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int (2010) 2.33
Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol (2010) 2.22
Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant (2007) 2.15
Hepatitis C treatment completion rates in routine clinical care. Liver Int (2009) 2.10
Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol (2013) 2.06
Mechanisms of anemia in CKD. J Am Soc Nephrol (2012) 1.91
Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis (2009) 1.79
Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol (2013) 1.78
Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab (2007) 1.77
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int (2009) 1.72
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol (2007) 1.70
Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A (2008) 1.70
Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis (2012) 1.69
Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol (2009) 1.67
Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ (2009) 1.61
Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol (2007) 1.61
Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int (2011) 1.61
Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol (2009) 1.59
Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med (2014) 1.58
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ (2009) 1.57
High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int (2011) 1.56
Biomarkers and surrogate endpoints in clinical trials. Stat Med (2012) 1.53
Immunosuppressive effects of erythropoietin on human alloreactive T cells. J Am Soc Nephrol (2014) 1.53
Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol (2012) 1.52
CKiD (CKD in children) prospective cohort study: a review of current findings. Am J Kidney Dis (2012) 1.48
Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev (2013) 1.47
The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol (2010) 1.46
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer (2010) 1.46
Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis (2010) 1.43
Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth (2011) 1.43
Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. Eur J Heart Fail (2015) 1.41
Asymmetric Dimethylarginine Contributes to the Impaired Response to Erythropoietin in CKD-Anemia. J Am Soc Nephrol (2017) 1.39
Outcomes Associated with Conventional Accelerated Versus Once-Weekly IV Iron Therapy in Outpatients Undergoing Hemodialysis. Can J Hosp Pharm (2015) 1.38
Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med (2008) 1.36
Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int (2008) 1.34
C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol (2008) 1.34
Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic Renal Insufficiency Cohort (CRIC) study. Clin J Am Soc Nephrol (2010) 1.32
Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol (2009) 1.29
Erythropoietin. Cold Spring Harb Perspect Med (2013) 1.28
Anemia, diabetes, and chronic kidney disease. Diabetes Care (2009) 1.27
High prevalence of sickle cell trait in African Americans with ESRD. J Am Soc Nephrol (2010) 1.23
Anemia status, hemoglobin concentration and outcome after acute stroke: a cohort study. BMC Neurol (2010) 1.22
Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens (2010) 1.21
Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria. Expert Rev Anti Infect Ther (2010) 1.20
Chronic kidney disease and its complications. Prim Care (2008) 1.19
Fatigue in patients receiving maintenance dialysis: a review of definitions, measures, and contributing factors. Am J Kidney Dis (2008) 1.18
Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. J Am Soc Nephrol (2015) 1.16
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients. J Am Soc Nephrol (2015) 1.16
Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol (2008) 1.14
Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage? Nephrol Dial Transplant (2009) 1.13
Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol (2009) 1.13
An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. Milbank Q (2011) 1.12
Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ (2008) 1.12
Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol (2014) 1.11
Drug-induced hematologic syndromes. Adv Hematol (2009) 1.11
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant (2008) 1.10
Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol (2009) 1.10
Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus (2009) 1.09
Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol (2009) 1.09
Neuropsychiatric complications of chronic kidney disease. Nat Rev Nephrol (2010) 1.08
Medicare's payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs. Health Aff (Millwood) (2012) 1.07
FLT3/ITD AML and the law of unintended consequences. Blood (2011) 1.07
Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Physiol Renal Physiol (2010) 1.07
Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol (2013) 1.06
Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopath Med Prim Care (2007) 1.06
Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients. Clin J Am Soc Nephrol (2007) 1.06
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost (2012) 1.05
Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol (2008) 1.05
Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.05
The role of anemia management in improving outcomes for African-Americans with chronic kidney disease. Am J Nephrol (2008) 1.04
Observational studies versus randomized controlled trials: avenues to causal inference in nephrology. Adv Chronic Kidney Dis (2012) 1.04
Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol (2009) 1.03
Risk factors for progression of chronic kidney disease. Curr Opin Pediatr (2010) 1.03
Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol (2011) 1.02
Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol (2008) 1.02
Erythropoietin activates mitochondrial biogenesis and couples red cell mass to mitochondrial mass in the heart. Circ Res (2010) 1.01
Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol (2009) 1.01
Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Clin J Am Soc Nephrol (2010) 1.00
The cardiorenal syndrome: a review. Int J Nephrol (2010) 1.00
The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol (2008) 1.00
Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients. Saudi J Gastroenterol (2008) 1.00
Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL. Clin J Am Soc Nephrol (2009) 1.00
Chapter 3: Use of ESAs and other agents to treat anemia in CKD. Kidney Int Suppl (2011) (2012) 1.00
Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol (2010) 1.00
Impacts of chronic kidney disease and albuminuria on associations between coronary heart disease and its traditional risk factors in type 2 diabetic patients - the Hong Kong diabetes registry. Cardiovasc Diabetol (2007) 0.99
Management of anemia in chronic kidney disease patients: baseline findings from Chronic Kidney Disease Japan Cohort Study. Clin Exp Nephrol (2011) 0.99
Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant (2010) 0.99
Threshold haemoglobin levels and the prognosis of stable coronary disease: two new cohorts and a systematic review and meta-analysis. PLoS Med (2011) 0.99
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int (2008) 3.34
KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis (2013) 2.43
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
National profile of practice patterns for hemodialysis vascular access in the United States. J Am Soc Nephrol (2002) 1.79
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int (2009) 1.72
A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia. Clin J Am Soc Nephrol (2009) 1.52
Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients. Am J Kidney Dis (2007) 1.32
Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci (2013) 1.31
Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS (2009) 1.26
Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis (2008) 1.25
A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clin J Am Soc Nephrol (2008) 1.24
Health status and quality of life reported by incident patients after 1 year on haemodialysis or peritoneal dialysis. Nephrol Dial Transplant (2005) 1.23
Multimorbidity and risk among patients with established cardiovascular disease: a cohort study. Br J Gen Pract (2008) 1.23
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol (2007) 1.19
Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol (2008) 1.18
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol (2003) 1.15
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther (2014) 1.10
A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood (2011) 1.09
Metabolic acidosis in maintenance dialysis patients: clinical considerations. Kidney Int Suppl (2003) 1.07
Volumetric quantification of lung nodules in CT with iterative reconstruction (ASiR and MBIR). Med Phys (2013) 1.05
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology (2013) 1.03
Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg (2003) 1.02
Percutaneous abscess drainage in patients with perforated acute appendicitis: effectiveness, safety, and prediction of outcome. AJR Am J Roentgenol (2010) 1.00
Detection of pancreatic tumors, image quality, and radiation dose during the pancreatic parenchymal phase: effect of a low-tube-voltage, high-tube-current CT technique--preliminary results. Radiology (2010) 1.00
Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr (2013) 0.97
Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study. Am J Kidney Dis (2009) 0.95
Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial Transplant (2005) 0.95
Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl (2002) 0.94
Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study. Nephrol Dial Transplant (2007) 0.93
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med (2002) 0.90
Prevalence of kidney disease in HIV-infected and uninfected Rwandan women. PLoS One (2011) 0.90
Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol (2004) 0.89
Regional variability in anaemia management and haemoglobin in the US. Nephrol Dial Transplant (2003) 0.89
Quantitative CT: technique dependence of volume estimation on pulmonary nodules. Phys Med Biol (2012) 0.89
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol (2013) 0.88
Cost, quality, and value: the changing political economy of dialysis care. J Am Soc Nephrol (2007) 0.87
Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med (2012) 0.87
The impact of renal insufficiency and anaemia on survival in patients with cardiovascular disease: a cohort study. BMC Cardiovasc Disord (2009) 0.86
Diagnostic accuracy of intra-abdominal fluid collection characterization in the era of multidetector computed tomography. Am Surg (2012) 0.86
The patient-centered medical home and nephrology. J Am Soc Nephrol (2009) 0.83
Early quality of life benefits of icodextrin in peritoneal dialysis. Kidney Int Suppl (2002) 0.82
Gray-scale inversion radiographic display for the detection of pulmonary nodules on chest radiographs. Clin Imaging (2012) 0.82
Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis (2015) 0.82
Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis (2012) 0.81
A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia. Clin J Am Soc Nephrol (2010) 0.81
Reduced kidney function and preclinical atherosclerosis in HIV-infected individuals: the study of fat redistribution and metabolic change in HIV infection (FRAM). Am J Nephrol (2011) 0.80
Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR. Nephrol Dial Transplant (2012) 0.80
Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. J Interv Cardiol (2003) 0.78
Anaemia of CKD--the CHOIR study revisited. Nephrol Dial Transplant (2007) 0.78
Potential role of bone morphogenetic protein (BMP) signalling as a potential therapeutic target for modification of iron balance. Nephrol Dial Transplant (2008) 0.77
Association of race and age with survival among patients undergoing dialysis: racial differences on many levels. Kidney Int (2011) 0.77
Effects of intraperitoneal hyaluronan on peritoneal fluid and solute transport in peritoneal dialysis patients. Perit Dial Int (2003) 0.76
Diuretic use and ESRD, precipitating factor or epiphenomenon. Am J Hypertens (2005) 0.75
Journal club. Cystatin C and contrast-induced acute kidney injury. Kidney Int (2010) 0.75
Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. BMC Res Notes (2014) 0.75
Management of ischemic heart disease in patients with chronic kidney disease. Am J Cardiovasc Drugs (2008) 0.75
Central, peripheral, and other blood volume changes during hemodialysis. ASAIO J (2002) 0.75
Anemia trials: lessons for clinicians, politicians, and third-party payers. Kidney Int (2010) 0.75
ASN clinicopathologic conference. Clin J Am Soc Nephrol (2011) 0.75
Chronic kidney disease: Association between ESA use and stroke in patients with CKD. Nat Rev Nephrol (2011) 0.75
Women in medicine: achieving tenure at home and work--prioritization is a personal decision. Kidney Int (2008) 0.75
Uses and interpretation of iron studies in patients on chronic dialysis. Semin Dial (2014) 0.75
Standards of practice for nutrition support physicians. Nutr Clin Pract (2003) 0.75
64-section multidetector CT of the upper abdomen: optimization of a saline chaser injection protocol for improved vascular and parenchymal contrast enhancement. Eur Radiol (2011) 0.75